Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Creo Medical GroupCMEOF 29 EV-to-EBITDA is -3.64 as of Jul. 29, 2026. GuruFocus rates CMEOF with a GF Score™ of 29/100 and a GF Value™ of $0.38 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 512 Medical Devices & Instruments companies, Creo Medical Group ranks worse than 195312.3% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Creo Medical Group's enterprise value is $77.74 Mil.
Creo Medical Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-21.38 Mil. Therefore, Creo Medical Group's EV-to-EBITDA for today is -3.64.
The historical rank and industry rank for Creo Medical Group's EV-to-EBITDA or its related term are showing as below:
CMEOF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -14.56 Med: -2.82 Max: -0.31
Current: -3.57
During the past 11 years, the highest EV-to-EBITDA of Creo Medical Group was -0.31. The lowest was -14.56. And the median was -2.82.
CMEOF's EV-to-EBITDA is ranked worse than 100% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.25
vs CMEOF: -3.57
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Creo Medical Group (OTCPK:CMEOF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Creo Medical Group's PE Ratio (TTM) for today is calculated as:
Creo Medical Group's share price for today is $0.2256.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Creo Medical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.014.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Creo Medical Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Creo Medical Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creo Medical Group EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Creo Medical Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Creo Medical Group's EV-to-EBITDA falls into.
Creo Medical Group's current Enterprise Value is $77.74 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Creo Medical Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-21.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creo Medical Group (CMEOF) has a EV-to-EBITDA of -3.64 as of Jul. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Creo Medical Group. According to the industry distribution chart, Creo Medical Group ranks #999999 out of 512 companies in the Medical Devices & Instruments industry.
Is Creo Medical Group's EV-to-EBITDA too high?
Creo Medical Group's current EV-to-EBITDA is -3.64. Based on the distribution chart, Creo Medical Group ranks #999999 out of 512 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Creo Medical Group has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Creo Medical Group's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Creo Medical Group ranks #999999 out of 512 companies for EV-to-EBITDA. This places Creo Medical Group in the lower half of its industry. The industry median EV-to-EBITDA is 14.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.25, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Creo Medical Group. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creo Medical Group's current EV-to-EBITDA is -3.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creo Medical Group stock overvalued right now?
Based on GuruFocus' analysis, Creo Medical Group (CMEOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.38, compared to a current price of $0.23 — trading 40.6% below its estimated fair value. The current EV-to-EBITDA is -3.64. Creo Medical Group's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Creo Medical Group (CMEOF), the current EV-to-EBITDA is -3.64 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Creo Medical Group (CMEOF) Overvalued in 2026?
Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued.
The current stock price of $0.23 is trading 40.6% below its estimated GF Value™ of $0.38.
GuruFocus considers Creo Medical Group to be Possible Value Trap.
Key valuation signals for CMEOF:
EV-to-EBITDA: -3.64
GF Value™: $0.38 vs. price of $0.23 (40.6% below fair value)
No single metric tells the full story. See the CMEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
29GF Score
Get the complete analysis for CMEOF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMEOF has been successfully added to your 
